Chemours: Barclays initiates coverage with equal-weight rating and $16 target price
CC•Barclays initiated coverage of Chemours with an equal-weight rating and a $16 target price.
Related News
Wuhan Hiteck grants Visara exclusive rights to HT006.2.2 outside Greater China
NBP•
Kimberly-Clark receives requisite consents for amendments to all Kenvue notes
KMB•
Alaunos Therapeutics completes acquisition of Velaris Therapeutics
TCRT•
Dolphin Entertainment CEO William O'Dowd IV buys $4,784 of common shares
DLPN•
BP sees Q3 net debt at USD 13.5 billion-14.5 billion
BP•